Drug recall · June 22, 2022
medroxyPROGESTERone Acetate Injectable Suspension recall
Why: Lack of assurance of sterility
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
medroxyPROGESTERone Acetate Injectable Suspension, USP, 1 mL Prefilled Syringe, 150 mg/mL, Rx only, Manufactured by: Sun Pharmaceutical Industries, Ltd., Halol-Baroda Highway, Halol-389 350, Gujarat, India Distributed by: Afaxys Pharma, LLC, Charleston, SC, 29403, USA, Product of Italy, NDC 50102-591-40.
- Lots / codes
Lots#: JKX4312A & JKX4313A, Exp 09/2022; JKX4827A, Exp 09/2023; HAC1290A & HAC2082B, Exp 06/2023;
- Quantity
- 79339 syringes
- Company
- Sun Pharmaceutical Industries Inc, Princeton, NJ
- Distribution
- USA Nationwide
- Initiated
- May 6, 2022 · Voluntary: Firm initiated
- Classified
- June 10, 2022
- Reported
- June 22, 2022
- Ended
- August 14, 2023
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Medroxyprogesterone
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.